Medical News

Risk Factors for BSI in Patients with Severe ARDS Supported...
BMC Pulm Dis.

The incidence of bloodstream infection (BSI) in patients with severe ARDS supported by VV–ECMO was 22%. G– bacilli...

29 Sep 2022

Poor Timing and Failure of Source Control are Risk Factors f...
Intensive Care Med.

‘Urgent’ and successful source control was associated with improved odds of survival. Appropriateness of empirical...

26 Sep 2022

Factors Associated with The Decision to Administer Β-Lactams...
Int J Infect Dis.

Prolonged infusion (PI) for administering β-lactams was not a commonly applied strategy in sepsis and was more...

23 Sep 2022

Cystatin C and Derived Measures of Renal Function as Risk Fa...
J Crit Care.

Cystatin C and derived measures of kidney function at ICU admission are associated with an increased 90-day...

15 Sep 2022

Key Trials

Treatment with Casirivimab and Imdevimab Lowers Hospitalization Rates in High Risk Patients with Mild-to-Moderate COVID-19

The results of this real-world study demonstrated that treatment with casirivimab-imdevimab significantly lowered the rate of hospitalization among...

Casirivimab and Imdevimab Antibody Cocktail Clinically Beneficial in High Risk COVID-19 Patients

Casirivimab and Imdevimab antibody cocktail resulted in lesser requirement of mechanical ventilation and high-flow oxygen with no deaths as compared...

RECOVERY Trial: Efficacy and Safety of Casirivimab and Imdevimab Combination in Hospitalized COVID-19 Patients

RECOVERY Trial evaluated efficacy and safety of casirivimab and imdevimab combination in hospitalized COVID-19 patients. The study showed that in...

REGEN-COV Reduces Risk of Hospitalization and Shortens Time to Resolution of Symptoms in Symptomatic COVID-19 Patients

As per the results of this phase 3, administration of REGEN-COV decreased the risk of Covid-19–related hospitalization or death from any cause....

Slide Library

Cefuroxime (Novacef)

Cefuroxime is a second-generation cephalosporin antibiotic. It is a broad-spectrum antibacterial agent with a favorable pharmacokinetic profile....

 
Email this page
Management of Mucormycosis in ENT Practice

Mucormycosis are the group of invasive infection caused by filamentous fungi of the Mucoraceae family. This slide set enumerates prevalence,...

 
Email this page
Antifungal Therapy in Immunocompromised Patients

Early initiation of antifungal therapy is a major contributor to enhanced survival rate. This set of slides highlights incidence and risk factors of...

 
Email this page
Disseminated Tuberculosis with ARDS

Disseminated TB results from widespread blood borne dissemination of TB bacilli. This presentation includes causes and risk factors of disseminated...

 
Email this page

Our Publications

Barijak (Barictinib) Monograph

Barictinib can be useful addition for treatment of Moderate to Severe Covid 19 patients in combination with Remdesivir. Barcitinib inhibits the...

Cipmolnu (Molnupiravir) Monograph

This monograph overviews in-vitro/clinical evidence for Molnupiravir efficacy, safety and positioning.

Molnupiravir: Fact Sheet for Healthcare Givers and Recipients

This fact sheet contains the factual details about the drug molnupiravir, its restricted use under emergency situation, dosage, side effects etc....

Molnupiravir - FAQ Booklet

This document addresses frequently asked questions related to oral antiviral drug Molnupiravir in the treatment of Covid-19.